about
Role of Components in the Formation of Self-microemulsifying Drug Delivery SystemsPharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulationsFormulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies.Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdlesStyrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery - dual uptake through enterocytes and M-cells.Dual-channel in-situ optical imaging system for quantifying lipid uptake and lymphatic pump function.A Self-microemulsifying Drug Delivery System (SMEDDS) for a Novel Medicative Compound Against Depression: a Preparation and Bioavailability Study in Rats.Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity.Advanced drug delivery to the lymphatic system: lipid-based nanoformulations.Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Nanoemulsion-based oral delivery systems for lipophilic bioactive components: nutraceuticals and pharmaceuticals.Self-microemulsifying drug delivery system (SMEDDS)--challenges and road ahead.Excipient foods: designing food matrices that improve the oral bioavailability of pharmaceuticals and nutraceuticals.Lipid-based drug carriers for prodrugs to enhance drug delivery.Glucose-Based Mesoporous Carbon Nanospheres as Functional Carriers for Oral Delivery of Amphiphobic Raloxifene: Insights into the Bioavailability Enhancement and Lymphatic Transport.Lipoproteins and lipoprotein mimetics for imaging and drug delivery.Self-Microemulsifying Drug Delivery Systems: An Attractive Strategy for Enhanced Therapeutic Profile.Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.microRNAs in the Lymphatic Endothelium: Master Regulators of Lineage Plasticity and Inflammation.Demonstration of ATP-dependent, transcellular transport of lipid across the lymphatic endothelium using an in vitro model of the lacteal.Review and analysis of FDA approved drugs using lipid-based formulations.Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative.Enhanced lymphatic transport of bioactive lipids: cell culture study of polymethoxyflavone incorporation into chylomicrons.Formulation optimization and the absorption mechanisms of nanoemulsion in improving baicalin oral exposure.Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.Directed self-assembled nanoparticles of probucol improve oral delivery: fabrication, performance and correlation.Biopharmaceutical insights of particulate emulsified systems - a prospective overview.
P2860
Q26801043-F313A938-87D5-439F-84A1-4C371A4A0C05Q28084784-B314AD30-AF88-41E0-A1A8-79BFABD421ACQ33568609-1B80DD14-8226-49B5-8CD4-5E98F327CCF8Q33683206-ADE1C245-13E0-4A05-B416-E37FE8D983EAQ35892628-F40AC74C-6B97-46B6-9E39-604ABB0E5257Q36147491-8DC7BEB0-449B-4ED2-A7DD-C740514DD019Q36360531-EEFB0AA5-6481-4601-BAC1-53CA4456AA60Q36949647-0BEAE53E-4C42-4CB0-920B-E69B7FF5D38FQ37066550-0139AC80-306C-460E-ADE1-D5FEF8183C13Q37587740-77C18B1C-1542-4892-B6EF-A0A0D3EBD9ADQ38017299-ADF4BCF7-6C00-452D-948B-CC39DF5FF150Q38082728-2A8F0D03-C9E4-4D26-B84D-1F957010C1C7Q38123857-6F4DE38A-98B2-443B-95B9-A6ABC642252BQ38199539-DCA267FD-8F97-482E-AF88-9DE1C3D9261FQ38206716-0E6FB3D0-5AEC-471D-83D5-415CA1DFA9C9Q38255590-CEA03FB1-C3B9-4B30-B0B6-99DF7A2B820AQ38820627-3BBB23DA-7680-446E-9D47-36DCB24EE43EQ38822339-7D673947-8413-4A41-B188-7516488C9492Q38887547-A76DA95B-C663-4D38-8E18-39E9EB598A03Q38926514-E414ED2F-15E8-4485-B57F-8DF1F9ED4DC5Q39148619-31E137A1-9D3E-45C9-A980-28FABAE6BB0CQ39311671-7AA673CE-EC91-48BA-A66C-E38DD25E2E03Q39411779-34D8ECED-7FAE-4216-98A6-DE17A60B0D2CQ42366841-C37C083E-894A-4321-8486-3E8C92F38BC9Q44623060-53B9B212-3A3C-45DA-A833-7F43EED97ED4Q50096655-BAC38A6E-78A7-492D-833F-E8DB36127CF3Q51242631-6F9C0595-82E3-4CCF-9608-2878098F98B8Q51750624-84F851B3-0453-4E35-ABA8-D58903B882F4Q55004938-7D1144BE-2F2D-46F2-8831-4F260496E180
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intestinal lymphatic transport for drug delivery.
@en
Intestinal lymphatic transport for drug delivery.
@nl
type
label
Intestinal lymphatic transport for drug delivery.
@en
Intestinal lymphatic transport for drug delivery.
@nl
prefLabel
Intestinal lymphatic transport for drug delivery.
@en
Intestinal lymphatic transport for drug delivery.
@nl
P2093
P1476
Intestinal lymphatic transport for drug delivery.
@en
P2093
Ian W Knemeyer
Jaime A Yáñez
Kevin B Alton
Mark A Wirth
Stephen W J Wang
P304
P356
10.1016/J.ADDR.2011.05.019
P407
P577
2011-06-13T00:00:00Z